Analysts rate US firm Znomics as a "speculative buy" with $4 price target
Independent firm Beacon Equity Research's analyst Victor Sula has issued a report that rates US biotechnology company Znomics as a "Speculative Buy" and giving it a $4.00 price target.
Znomics is a biotechnology company leveraging its proprietary Zebrafish genetic technology platform using medicinal chemistry and in vivo compound screening for the development of advanced preclinical drugs to treat obesity, cancer and inflammation. The firm believes Zebrafish models are ideal for drug discovery since the fish mature quickly, are highly fertile and share around 80% to 90% of the genes found in humans.
Zebrafish platforms give higher throughput
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze